

Product Datasheet

Monalizumab Biosimilar (NKG2A / CD94 Reference Antibody) (orb2704016)

Catalog Number	orb2704016
Category	Antibodies
Description	Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN- γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Target	Monalizumab Biosimilar / Anti-NKG2A / CD94 Reference Antibody
Clonality	Monoclonal
Conjugation	Unconjugated
Purity	>98%
Antibody Type	Inhibitor Antibody
CAS Number	1228763-95-8
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Note	For research use only
Expiration Date	12 months from date of receipt.

Biorbyt Ltd.

7 Signet Court, Swann Road
Cambridge
CB5 8LA
United Kingdom

Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\)1223 859353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)651-8558)

Biorbyt LLC

68 TW Alexander Drive
Research Triangle Park
Durham
NC 27713-2847
United States

Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)906-5211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)651-8558)